DMRA
$21.96+3.29%
Damora Therapeutics Inc.Stock · HealthcareRussell 2000 · 0.04% of IWMNasdaq Composite · 0.004% of ONEQRussell 3000 · 0.002% of IWV
DMRA financial statements
The full income statement, balance sheet, and cash-flow statement for Damora Therapeutics Inc. (DMRA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 1.1M2024-09 1.3M2024-12 1.3M2025-03 1.3M2025-06 1.3M2025-09 1.3M2025-12 60.3M2026-03 61.6M2026-06 61.7M+5588.8% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 211M+847.3% | 22.3M-44.2% | 39.9M-34.8% | 61.2M+17.2% | 52.2M+55.3% | ||
| Research & development | 26.9M+320.1% | 6.40M-73.1% | 23.8M-50.7% | 48.2M+25.2% | 38.5M+56.3% | |
| Selling, general & administrative | 9.69M-7.8% | 10.5M-17.2% | 12.7M-2.4% | 13.0M-5.4% | 13.7M+52.5% | |
| General & administrative | 9.69M-7.8% | 10.5M-17.2% | 12.7M-2.4% | 13.0M-5.4% | 13.7M+52.5% | |
| Restructuring | — | 968K-71.9% | 3.45M | — | — | |
| Operating income | -211M-847.3% | -22.3M+44.2% | -39.9M+34.8% | -61.2M-17.2% | -52.2M-55.3% | |
| Net interest income | 1.17M+38.3% | 844K-50.0% | 1.69M+133.9% | 722K+362.8% | 156K | |
| Other non-operating income | 1.08M+25.6% | 862K-44.6% | 1.56M+473.1% | -417K-187.8% | 475K+139.6% | |
| Gain (loss) on equity securities | — | — | 231K+189.2% | -259K-236.4% | -77.0K | |
| Pre-tax income | -210M-880.4% | -21.4M+44.2% | -38.3M+37.8% | -61.6M-19.1% | -51.8M-48.6% | |
| Income tax | 50.0K+22.0% | 41.0K | 0.00 | 0.00 | 0.00 | |
| Net income | -210M-878.8% | -21.4M+44.1% | -38.3M+37.8% | -61.6M-19.1% | -51.8M-48.6% | |
| $3.98+121.5% | -$18.53+48.6% | -$36.08+40.6% | -$60.75-18.5% | -$51.25 | ||
| EPS (basic) | $3.98+121.5% | -$18.53+48.6% | -$36.08+40.6% | -$60.75-18.5% | -$51.25 | |
| Weighted-avg shares (basic) | 1.36M+17.8% | 1.16M+8.9% | 1.06M+4.6% | 1.02M+0.6% | 1.01M | |
| Weighted-avg shares (diluted) | 1.36M+17.8% | 1.16M+8.9% | 1.06M+4.6% | 1.02M+0.6% | 1.01M | |
| Dividends per share | $0.00 | $0.00 | — | — | $0.00 | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 260M+1446.5% | 16.8M-54.2% | 36.8M-42.5% | 63.9M-42.0% | 110M-35.0% | ||
| Cash & equivalents | 258M+1717.5% | 14.2M-34.0% | 21.5M-34.5% | 32.8M-47.6% | 62.6M-61.8% | |
| Short-term investments | — | — | 11.7M-57.4% | 27.4M-27.1% | 37.6M | |
| Prepaid expenses | 2.80M+5.1% | 2.66M-26.5% | 3.62M-1.7% | 3.69M-62.8% | 9.91M+73.5% | |
| 261M+1420.7% | 17.1M-55.2% | 38.2M-47.8% | 73.2M-40.1% | 122M-28.8% | ||
| Property, plant & equipment | 36.0K-36.8% | 57.0K-26.9% | 78.0K-78.2% | 357K+75.9% | 203K | |
| Operating lease right-of-use | 68.0K-6.8% | 73.0K-70.4% | 247K-69.5% | 810K-2.9% | 834K-5.8% | |
| Long-term investments | — | — | — | 5.83M-35.5% | 9.05M | |
| Other non-current assets | 104K-36.2% | 163K-85.5% | 1.13M-50.5% | 2.28M+12.4% | 2.03M+74.5% | |
| 20.1M+1576.4% | 1.20M-79.5% | 5.83M-47.5% | 11.1M+144.4% | 4.54M-18.4% | ||
| Accounts payable | 444K+17.8% | 377K-77.8% | 1.70M-49.2% | 3.35M+118.8% | 1.53M-46.3% | |
| Accrued liabilities | 2.40M+192.8% | 820K-80.1% | 4.13M-46.8% | 7.76M+157.5% | 3.01M+11.0% | |
| Current lease liability | 15.0K+25.0% | 12.0K-93.4% | 183K-61.6% | 476K+19.3% | 399K+6.7% | |
| 20.1M+1448.6% | 1.30M-77.9% | 5.90M-48.4% | 11.4M+129.1% | 4.99M-18.3% | ||
| Non-current lease liability | 53.0K-13.1% | 61.0K-7.6% | 66.0K-79.9% | 328K-26.8% | 448K-17.2% | |
| Operating lease liability (total) | 68.0K-6.8% | 73.0K-70.7% | 249K-69.0% | 804K-5.0% | 846K-7.5% | |
| Other non-current liabilities | 81.0K+88.4% | 43.0K | — | — | — | |
| 240M+1418.4% | 15.8M-51.0% | 32.3M-47.6% | 61.8M-47.3% | 117M-29.2% | ||
| Additional paid-in capital | 311M+6.4% | 292M+1.3% | 288M+3.0% | 280M+2.2% | 274M+1.7% | |
| Retained earnings | -487M-75.6% | -278M-8.4% | -256M-17.6% | -218M-39.5% | -156M-49.6% | |
| Accumulated other comprehensive income | 802K+726.8% | 97.0K-74.5% | 380K+255.7% | -244K+23.8% | -320K-147.5% | |
| Total liabilities & equity | 261M+1420.7% | 17.1M-55.2% | 38.2M-47.8% | 73.2M-40.1% | 122M-28.8% | |
| Common shares issued | 1.60M+21.3% | 1.32M+21.4% | 1.08M+5.7% | 1.03M+1.5% | 1.01M+0.0% | |
| Common shares outstanding | 1.60M+21.3% | 1.32M+21.4% | 1.08M+5.7% | 1.03M+1.5% | 1.01M+0.0% | |
| Shares outstanding (cover) | 60.3M+4460.3% | 1.32M+21.9% | 1.08M+5.6% | 1.03M+1.6% | 1.01M+0.0% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -6.73M+63.9% | -18.6M+49.5% | -36.9M+14.0% | -42.9M+17.9% | -52.3M-36.9% | ||
| Depreciation & amortization | 22.0K+4.8% | 21.0K-92.2% | 269K+540.5% | 42.0K+110.0% | 20.0K | |
| Share-based compensation | 998K-69.2% | 3.24M-40.3% | 5.43M-2.6% | 5.57M+24.4% | 4.48M+356.2% | |
| Change in payables | 51.0K+103.8% | -1.32M+19.6% | -1.65M-190.6% | 1.82M+237.8% | -1.32M-176.7% | |
| -17.4M-249.1% | 11.7M-47.8% | 22.3M+80.3% | 12.4M+125.8% | -48.0M | ||
| Capital expenditure | — | — | — | 196K-12.1% | 223K | |
| Free cash flow | — | — | — | -43.1M+17.9% | -52.5M | |
| Acquisitions | 17.4M | 0.00 | 0.00 | 0.00 | 0.00 | |
| Proceeds from sale of PP&E | — | — | 83.0K | — | — | |
| 267M | — | 2.88M+467.3% | 507K | — | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00-100.0% | 2.88M+467.3% | 507K | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | 705K+322.4% | -317K-182.6% | 384K+45.5% | 264K+128.8% | -917K-129.3% | |
| Income taxes paid | 5.00K | — | — | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.39B+22466.0% | 6.15M-68.5% | 19.5M-33.6% | 29.4M-61.6% | 76.5M-75.8% | |
| P/B | 5.8×+1386.2% | 0.4×-25.6% | 0.5×+29.1% | 0.4×-38.1% | 0.7×-65.8% | |
| Dividend yield | 0.00% | 0.00% | — | — | 0.00% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: DMRA’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all DMRA filings on SEC EDGAR → Not investment advice.